One of the goals of the Center for Cancer Genome Discovery (CCGD) is to provide basic, translational, and clinical investigators with access to our technologies. In this role, CCGD participates
in the design, execution, and analysis of both targeted and whole genome-focused projects.
Collaboration with CCGD offers access to cutting-edge genomic technology platforms and data analysis tools, as well as guidance in experimental design by experts in the field of cancer genomics. Not just Dana-Farber researchers, but all researchers and
clinicians focusing on cancer, will have access to CCGD's technologies.
Collaborators should contact CCGD's Associate Director, Aaron Thorner, PhD, or Scientific Director, Laura MacConaill, PhD, to outline their experimental
proposal. Following discussions with the appropriate CCGD members, the collaborator will submit a proposal form for review by the Proposal Evaluation Committee (PEC).
The PEC will conduct a review of proposed collaborations. The PEC is composed of the directors and CCGD faculty members with expertise in the particular project area, and one or more non-CCGD members
within Dana-Farber. The PEC will independently review each proposal based on a number of criteria:
The following policy statement reflects the approved operating policies and procedures established by the CCGD as summarized here and fully described in the CCGD Policies and Procedures.
CCGD: Aaron ThornerProfile: Elizabeth GarciaBioinformatics: Matthew Ducar
For general questions:617-582-7253 email@example.com